ImageneBio, Inc. (NASDAQ:IMA) Receives Average Rating of “Hold” from Brokerages

Shares of ImageneBio, Inc. (NASDAQ:IMA) have been given a consensus rating of “Hold” by the five analysts that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $29.00.

A number of brokerages have recently issued reports on IMA. HC Wainwright began coverage on ImageneBio in a research report on Friday, August 21st. They set a “buy” rating and a $28.00 price target on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of ImageneBio in a research report on Monday, June 29th.

Institutional Trading of ImageneBio

A number of hedge funds have recently added to or reduced their stakes in IMA. Stonepine Capital Management LLC purchased a new stake in shares of ImageneBio during the 2nd quarter worth about $539,044,000. Trails Edge Capital Partners LP purchased a new position in ImageneBio during the second quarter valued at $1,663,824. Hsbc Holdings PLC acquired a new stake in shares of ImageneBio in the second quarter valued at about $208,000. Cable Car Capital LP acquired a new stake in shares of ImageneBio in the second quarter valued at about $4,611,000. Finally, Blue Owl Capital Holdings LP purchased a new stake in shares of ImageneBio during the second quarter worth about $5,414,000. 75.00% of the stock is owned by hedge funds and other institutional investors.

ImageneBio Stock Performance

NASDAQ IMA opened at $5.00 on Tuesday. ImageneBio has a 52-week low of $3.94 and a 52-week high of $9.20. The firm’s 50 day moving average price is $5.55 and its 200-day moving average price is $5.66. The company has a market cap of $56.76 million, a PE ratio of -1.09 and a beta of 0.70.

ImageneBio (NASDAQ:IMA) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.27. On average, analysts forecast that ImageneBio will post -3.23 earnings per share for the current fiscal year.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.